News Pfizer takes pipeline blow as it abandons cardiomyopathy dru... Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease, after it proved ineffective in a phase 3 trial.
News As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.